CITF Research Results

CITF Research Results2023-10-27T10:53:53-04:00

Prevalence of SARS-CoV-2 antibodies in Alberta, pre-vaccine roll out

This is a summary, written by members of the CITF Secretariat, of: Charlton CL, Nguyen LT, Bailey A, Fenton J, Plitt SS, Marohn C, Lau C, Hinshaw D, Lutsiak C, Simmonds K, Kanji JN, Zelyas N, Lee N, Mengel M, Tipples G. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic. Microbiol Spectr. 2021 Sep 3;9(1):e0029121. [...]

September 14, 2021|Seroprevalence studies|

Latest Canadian Blood Services data show improvements in vaccine uptake and equity in vaccine coverage

The month of June saw many Canadians rolling up their sleeves for a COVID-19 vaccine. The latest results from the Canadian Blood Services’ serosurvey reflect this, with vaccine-induced seroprevalence soaring to 86% across Canada (excluding the Territories and Quebec), up from 60% the month prior. Most importantly, the gap in vaccine coverage among socioeconomic groups has narrowed considerably compared to previous months. And while [...]

September 7, 2021|Seroprevalence studies|

Not all immune responses are created equal: antibody responses 3-5 months post-vaccination with Moderna or Pfizer in long-term care residents

In a recent CITF-funded study, not yet peer-reviewed, researchers from McMaster University Dr. Andrew Costa and Dr. Dawn Bowdish, in collaboration with the COVID in Long Term Care Study Group, examined immunity responses to COVID-19 vaccines in nursing home residents after two doses of Moderna or Pfizer-BioNTech vaccines.

August 24, 2021|Long-term care & seniors|
Go to Top